Se Il Jang

Title: Se Il Jang: Innovator in Cytokine Fusion Proteins

Introduction

Se Il Jang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of innovative fusion proteins. His work focuses on enhancing the efficacy of pharmaceutical compositions through novel protein engineering techniques.

Latest Patents

Se Il Jang holds a patent for a fusion protein comprising an antigen binding domain and a cytokine trimer domain. This invention relates to a cytokine trimer domain where a first monomer and a second monomer are linked by a linker (dimer), and a third monomer is coupled by a knob-into-hole mechanism. The novel fusion protein, known as receptor-antibody conjugated (cell) engager (RACE), is created by replacing the constant region (Fc) of an antibody with the cytokine trimer domain. RACE exhibits superior binding ability to the target receptor compared to the parent antibody, along with excellent simultaneous binding ability to both the antigen and the target receptor. This innovation has potential applications as a bispecific pharmaceutical composition.

Career Highlights

Se Il Jang is currently associated with Ctcells, Inc., where he continues to advance his research in the field of cytokine fusion proteins. His work has garnered attention for its potential to improve therapeutic outcomes in various medical applications.

Collaborations

Se Il Jang collaborates with notable colleagues, including Kka Bi Son and Jeong Hyeon Bak. Their combined expertise contributes to the innovative research environment at Ctcells, Inc.

Conclusion

Se Il Jang is a key figure in the development of advanced cytokine fusion proteins, with a focus on enhancing therapeutic efficacy. His contributions to biotechnology are paving the way for new treatment options in the pharmaceutical industry.